GAS5 and chronic kidney disease: This prospective cross-sectional study quantified GAS5 levels in paired plasma and urine samples from 198 CKD patients (stratified by renal fibrosis scoring: mild: <25%, moderate: 25–50%, severe: ≥50% fibrotic area) and 20 healthy controls.